Abstract
The emergence of multidrug resistant-tuberculosis (MDR-TB), defined as Mycobacterium tuberculosis strains with in vitro resistance to at least isoniazid and rifampicin, has necessitated evaluation and validation of appropriate surrogate endpoints for treatment response in drug trials for MDR-TB. The trial that has demonstrated efficacy of bedaquiline, a diarylquinoline that inhibits mycobacterial ATP synthase, possesses the requisite features to conduct this evaluation. Approval of bedaquiline for use in MDR-TB was based primarily on the results of the controlled C208 Stage II study (ClinicalTrials.gov number, NCT00449644) including 160 patients randomized 1:1 to receive bedaquiline or placebo for 24 weeks when added to an 18-24-month preferred five-drug background regimen. Since randomization in C208 Stage II was preserved until study end, the trial results allow for the investigation of the complex relationship between sustained durable outcome with either Week 8 or Week 24 culture conversion as putative surrogate endpoints. The relationship between Week 120 outcome with Week 8 or Week 24 culture conversion was investigated using a descriptive analysis and with a recently developed statistical methodology for surrogate endpoi...Continue Reading
References
Sep 5, 2002·Statistics in Medicine·Georg Heinze, Michael Schemper
Aug 23, 2003·Biostatistics·M BuyseH Geys
Jan 14, 2005·Health Affairs·Thomas R Fleming
May 4, 2006·Annals of Internal Medicine·Timothy H HoltzVaira Leimane
Jun 6, 2009·The New England Journal of Medicine·Andreas H DiaconDavid F Mc Neeley
Feb 2, 2010·The Lancet Infectious Diseases·Robert S WallisAlimuddin Zumla
Apr 13, 2010·Tuberculosis·Geraint R Davies
Jun 1, 2008·Expert Review of Pharmacoeconomics & Outcomes Research·Ariel Alonso, Geert Molenberghs
Jun 8, 2012·The New England Journal of Medicine·Maria Tarcela GlerCharles D Wells
Oct 19, 2012·The New England Journal of Medicine·Myungsun LeeClifton E Barry
Oct 27, 2012·Schizophrenia Research·Mariët van BuurenRené S Kahn
May 15, 2013·PloS One·Patrick P J PhillipsAndrew J Nunn
Aug 14, 2013·PloS One·Robert S WallisNeal Thomas
Aug 21, 2014·The New England Journal of Medicine·Andreas H DiaconUNKNOWN TMC207-C208 Study Group
Mar 3, 2015·The Lancet. Respiratory Medicine·Ekaterina V KurbatovaMatteo Zignol
Apr 30, 2015·PloS One·Robert S WallisDavid Hermann
Sep 27, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Robert S Wallis, Thomas Peppard
Dec 10, 2015·The European Respiratory Journal·Alexander S PymUNKNOWN TMC207-C209 Study Group
Feb 6, 2016·BMC Medicine·Patrick P J PhillipsStephen H Gillespie
Feb 13, 2016·Biometrics·Ariel AlonsoTomasz Burzykowski
Dec 15, 2016·Statistics in Medicine·Ariel AlonsoPaul Meyvisch
Apr 28, 2017·American Journal of Respiratory and Critical Care Medicine·Andreas H DiaconBrian Dannemann
Sep 30, 2017·The Journal of Antimicrobial Chemotherapy·Elin M Svensson, Mats O Karlsson